CYP3A5 genotype does not influence the blood concentration of tacrolimus measured with the abbott immunoassay [6]

Clinical Chemistry

Volumn 51, Issue 11, 2005, Pages 2214-2215

  Moreton, Michelle ^a   Fredericks, Salim ^a   McKeown, Denise A ^a   Shiferaw, Elizabeth W ^a   MacPhee, Iain A M ^a   Johnston, Atholl ^b   Holt, David W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ALLOTRANSPLANTATION; ANALYSIS OF VARIANCE; CONTROLLED STUDY; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; IMMUNOASSAY; LETTER; MAJOR CLINICAL STUDY; PHENOTYPE; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; TACROLIMUS;

EID: 27444444510     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.056895     Document Type: Letter

References (3)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Bio Chem 1989;18:10388-95.
2. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
3. Macphee IA, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005;79:499-502.